Objective. To assess whether vasopressin V1a receptor blockade reduces the
abnormal vasoactive response to cold in patients suffering from Raynaud's p
henomenon (RP).
Methods. SR 49059, an orally active, non-peptidic vasopressin V1a receptor
antagonist, was given orally (300 mg once daily) to 20 patients with RP in
a single-centre, double-blind, placebo-controlled, randomized cross-over st
udy with two 7-day periods of treatment separated by 21 days of washout. Bi
lateral finger systolic blood pressure and skin temperature were assessed b
efore and after immersion of the hand in cold water for 3 min (15 degreesC)
during the screening phase and three times (before and 2 and 4 h after dru
g intake) on days 1 and 7 of each of the two treatment periods. Recovery of
digital pressure and skin temperature was measured 0, 10, 20 and 32 min af
ter the end of the cold immersion test.
Results. SR 49059 significantly attenuated the cold-induced fall in systoli
c pressure by 14.5% (95% confidence interval 0-29. P = 0.045) on the most a
ffected hand on day 7 compared with placebo. Temperature recovery after the
end of the cold test showed a trend to enhancement 2 and 4 h after SR 4905
9 on day 7 (P = 0.060 and P = 0.062 respectively). The beneficial effects o
n finger pressure and temperature recovery were obtained without changes in
supine blood pressure or in heart rate.
Conclusion. SR 49059 given orally once a day for 7 days to patients with RP
showed favourable effects compared with placebo on finger systolic pressur
e and temperature recovery after cold immersion, without inducing side-effe
cts.